布地奈德联合重组人干扰素α1b雾化吸入对儿童肺炎支原体肺炎的临床疗效研究

Clinical efficacy of budesonide combined with recombinant human interferonα1b aerosol inhalation on children with Mycoplasma pneumoniae pneumonia

目的研究布地奈德联合重组人干扰素α1b雾化吸入治疗儿童肺炎支原体肺炎(MPP)的疗效。方法选取120例肺炎支原体肺炎患儿,随机分为对照组(A组)、布地奈德组(B组)与布地奈德+重组人干扰素α1b组(C组),各40例。A组给予阿奇霉素抗感染,并给予止咳化痰及退热对症治疗,B组在A组基础上加用布地奈德雾化吸入,C组在A组基础上联合布地奈德及重组人干扰素α1b雾化吸入。比较三组患儿的临床疗效、炎性指标[C反应蛋白(CRP)、嗜酸性粒细胞(EOS)、乳酸脱氢酶(LDH)]、肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、FEV1/FVC]。结果治疗后,A、B、C组患儿的总有效率分别为77.5%、95.0%及97.5%,B组和C组患儿的总有效率明显高于A组,差异具有统计学意义(P<0.05);C组患儿的总有效率略高于B组,但差异无统计学意义(P>0.05)。治疗前,三组患儿的CRP、EOS、LDH水平比较,差异无统计学意义(P>0.05);治疗后,三组患儿的CRP、EOS、LDH水平均显著低于本组治疗前,B组和C组的CRP、EOS、LDH水平均显著低于A组,C组的CRP、EOS、LDH水平均显著低于B组,差异有统计学意义(P<0.05)。治疗前,三组患儿的FVC、FEV1、FEV1/FVC水平比较,差异无统计学意义(P>0.05);治疗后,三组患儿的FVC、FEV1、FEV1/FVC水平均显著高于治疗前,且B组和C组患儿的FVC、FEV1、FEV1/FVC均显著高于A组,C组患儿的FVC、FEV1、FEV1/FVC均显著高于B组,差异具有统计学意义(P<0.05)。结论治疗肺炎支原体肺炎患儿,在常规抗感染治疗基础上,布地奈德与重组人干扰素α1b联合雾化吸入临床疗效好,具有明显的抗炎作用,能在短时间内改善肺功能,治疗费用低,操作简单,值得临床推广应用。

Objective To study the efficacy of budesonide combined with recombinant human interferonα1b aerosol inhalation on children with Mycoplasma pneumoniae pneumonia(MPP).Methods A total of 120 children with Mycoplasma pneumoniae pneumonia were randomly divided into control group(group A),budesonide group(group B)and budesonide combined with recombinant human interferonα1b(group C),with 40 cases in each group.Group A received azithromycin for anti-infection,and symptomatic treatment of cough,phlegm,and fever,group B received budesonide aerosol inhalation on the basis of group A,and group C received budesonide combined with recombinant human interferonα1b aerosol inhalation.on the basis of group A The clinical efficacy,inflammatory indexes[C-reactive protein(CRP),eosinophils(EOS),lactate dehydrogenase(LDH)]and pulmonary function indexes[forced vital capacity(FVC),forced expiratory volume in the first second(FEV1),FEV1/FVC]of the three groups were compared.Results After treatment,the total effective rate of group A,group B and group C were 77.5%,95.0%and 97.5%.The total effective rate of group B and group C were obviously higher than those of group A,and the difference was statistically significant(P<0.05).The total effective rate of group C was a little higher than that of group B,but the difference was not statistically significant(P>0.05).Before treatment,there was no statistically significant difference in levels of CRP,EOS and LDH among the three groups(P>0.05).After treatment,the levels of CRP,EOS and LDH of the three groups were significantly lower than those before treatment;the levels of CRP,EOS and LDH of group B and group C were significantly lower than those of group A,and group C was obviously lower than group B.All the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in levels of FVC,FEV1 and FEV1/FVC among the three groups(P>0.05).After treatment,the levels of FVC,FEV1 and FEV1/FVC of the three groups were significantly higher than those before treatment;the levels of FVC,FEV1 and FEV1/FVC of group B and group C were significantly higher than those of group A,and group C was obviously higher than group B.All the difference was statistically significant(P<0.05).Conclusion Combination of budesonide and recombinant human interferonα1b aerosol inhalation on the basis of conventional anti-infective treatment shows good clinical efficacy on children with Mycoplasma pneumoniae pneumonia,which has obvious anti-inflammatory effects,and can improve lung function in a short time with low cost and simple operation.It is worthy of clinical promotion and application.